MetaCap

Immunome (IMNM) vs Trevi Therapeutics (TRVI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Trevi Therapeutics (TRVI) has outperformed Immunome (IMNM) over the past year, gaining 21.5% versus a loss of 15.3%. Over five years, TRVI leads with a +1235.0% price change compared with -7.5% for IMNM. Trevi Therapeutics is the larger company by market cap ($1.90 billion vs $1.85 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMNM-15.33%TRVI+21.47%
+82%+31%-20%
Nov 21, 20251 yearNov 20, 2026
IMNM-8.78%TRVI+1159.43%
+1788%+806%-176%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMNM versus TRVI key metrics
MetricIMNMTRVI
Share price$15.69$13.35
Market cap$1.85B$1.90B
1-day change-5.54%-2.70%
YTD return-26.96%+6.63%
1-year return-15.33%+21.47%
5-year return-7.54%+1235.00%
EPS (TTM)$-2.63$-0.40
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$6.94M—
Revenue growth (YoY)-23.23%—
Net income (latest FY)$-212.39M$-42.76M
Operating margin-3228.83%—
Net margin-3059.99%—
52-week high$30.06$20.22
52-week low$15.55$9.82
Distance from 52-week high-47.80%-33.98%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+123.90%+111.09%
Average volume1.36M2.00M
Shares outstanding118.07M142.56M
Employees26734
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TRVI has outperformed IMNM by 36.8 percentage points over the past year.

About Immunome

IMNM stock →

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 267 employees

About Trevi Therapeutics

TRVI stock →

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.

Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees

IMNM vs TRVI FAQ

Which is bigger, Immunome or Trevi Therapeutics?

Trevi Therapeutics (TRVI) is larger, with a market capitalization of $1.90B compared with $1.85B for Immunome (IMNM).

Which stock has performed better over the past year, IMNM or TRVI?

TRVI returned +21.47% over the past 12 months, compared with -15.33% for IMNM (price return, excluding dividends). Past performance does not predict future results.

Are Immunome and Trevi Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons